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KEY POINTS
 Traditional chemotherapies are used throughout the world in the treatment of cutaneous T-cell
lymphoma (CTCL).
 Both single and multiagent chemotherapies can benefit patients with CTCL.
 There currently are no data to support the use of traditional chemotherapies over other therapies
for CTCL. Therefore, in patients with less advanced disease, alternative therapies should be
considered.INTRODUCTION
Currently, no traditional chemotherapy agents are
Food and Drug Administration (FDA) approved for
the treatment of mycosis fungoides (MF) or Se´z-
ary syndrome (SS). Multiple chemotherapeutic
treatments for MF and SS, such as systemic ni-
trogen mustard and multiagent chemotherapy
regimens (eg, cyclophosphamide, adriamycin,
vincristine, and prednisone [CHOP]), were initially
used because of established activity in other non-
Hodgkin lymphomas (NHLs) or Hodgkin lym-
phomas. Over time, specific treatments were
reported by astute physicians to be particularly
effective in MF/SS, such as the Winkelmann
chlorambucil regimen. More recently, however, it
has been recognized that some of these regi-
mens, which are often characterized by signifi-
cant immunosuppression and toxicity, are not
more effective than agents described elsewhere
in this issue (eg, interferons [IFNs]).1 Neverthe-
less, these other “chemotherapeutic” agents
remain an important therapy option for some pa-
tients with MF/SS. This article describes thoseDisclosure: The authors declare no conflicts of interest a
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under the CC BY-NC-ND license (http://creativecommons.chemotherapeutic agents not discussed else-
where in this issue with a review of the data
supporting their use. Table 1 summarizes
single-agent therapies in MF/SS and Table 2
summarizes multiagent chemotherapies. Readers
are further referred to a comprehensive review on
the treatments used for SS and MF by Olsen and
colleagues2 for additional in-depth discussion of
many of the agents discussed later.ANTIMETABOLITES
Antimetabolites are typically low-molecular-
weight molecules with structures resembling
normal cellular constituents that act by disrupting
normal metabolic pathways. There are 3 common
subgroups: (1) purine analogs, (2) pyrimidine ana-
logs, and (3) folates.
Purine Analogs/Antagonists
Purine analogs are antimetabolites with a chemical
structure that mimics the purine bases (adenine
and guanine) and interferes with DNA polymerasessociated with this work.
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Table 1
Summary of single-agent and combination chemotherapy studies in the treatment of mycosis fungoides or Se´zary syndrome
Agent(s) Response Rate (Responders/Total) Dosing Study
Fludarabine 2/5 25 mg/m2  5 d, q3–4 wk Redman et al,4 1992
6/31 18–25 mg/m2  5 d, q4 wk Von Hoff et al,5 1990
Fludarabine 1 ECP 7/27 MF; 6/17 SS 25 mg/m2  5 d, q4 wk Quaglino et al,6 2000
Fludarabine 1 IFN 18/35 25 mg/m2  5 d q4 wk; 5 million units, TIW Foss et al,7 1994
Fludarabine 1 cyclophosphamide 5/6 18 mg/m2  3 d, q4wk; 250 mg/m2  3 d, q4wk Scarisbrick et al,8 2011
Cladribine 2/2 0.1 mg/kg  7 d, q4wk Betticher et al,9 1994
2/9 4 mg/m2  7 d, q4wk O’Brien et al,10 1994
9/22 0.1 mg/kg  5–7 d, q4wk Kuzel et al,11 1996
2/8 0.06 mg/kg  5 d, q4wk Trautinger et al,12 1999
Pentostatin 10/32 3.75–5 mg/m2  3 d, q3wk Tsimberidou et al,14 2004
4/8 5 mg/m2  3 d, q3wk Cummings et al,15 1991
7/18 Varied Greiner et al,17 1997
5/22 MF; 7/21 SS 4 mg/m2 q1–4wk Ho et al,18 1999
4/6 MF; 10/14 SS 5 mg/m2  3 d, q3wk  1.25 mg/m2 on subsequent
cycles
Kurzrock et al,19 1999
Pentostatin, cyclophosphamide,
and bexarotene
5/5 MF; 2/3 SS 4 mg/m2 q2wk; 600 mg/m2 q2wk; 300 mg/m2 qd 
8 mo
Calderon Cabrera et al,21
2013
Pentostatin 1 IFN 17/41 4 mg/m2  3 d Foss et al,20 1992
Gemcitabine 9/19 1200 mg/m2 d 1, 8, 15, and 28 Zinzani et al,144 2010
19/26 MF; 0/1 SS 1200 mg/m2 d 1, 8, 15, and 28 Marchi et al,29 2005
21/30 1000 mg/m2 d 1, 8, and 15 Duvic et al,30 2006
3/3 1000 mg/m2 d 1, 8, and 15 then 250 mg/m2 weekly Buhl et al,32 2009
7/9 MF; 2/4 SS 1000 mg/m2 d 1 and 8 of a 21-d cycle or d 1, 8,  15
of a 28-d cycle
Jidar et al,31 2009
Mechlorethamine 34/41 Varied Van Scott et al,37 1975
Chlorambucil 1 prednisone 23/26 (all SS) 2–6 mg/d; 20 mg/d Winkelmann et al,44 1984
6/6 2–6 mg/d; 5–20 mg/d Hamminga et al,42 1979
Chlorambucil 1 fluocortolone 13/13 Clorambucil 10–12 mg/d  3 d; fluocortolone
75 mg d 1, 50 mg d 2, 25 mg d 3
Coors & von den Driesch,43
2000
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Chlorambucil 1 prednisone 1
leukapheresis
11/11 4 mg/d; 20 mg/d; Leukapheresis 2–3  per wk Winkelmann et al,44 1984
Bendamustine 2/3 60–100 mg/m2 Zaja et al,59 2013
Cyclophsphamide 4/4 Varied: 200–700 mg/d Abele & Dobson,61 1960
5/11 Varied: 50–300 mg/d Van Scott et al,66 1962
TMZ 3/9 150 mg/m2/d  5 d, q4wk, Then 200 mg/m2/d 
5 d q4wk
Tani et al,75 2005
7/26 200 mg/m2/d PO  5 d q4wk Querfeld et al,76 2011
Liposomal daunorubicin 3/3 20–40 mg/m2 q3–4wk Wollina et al,92 2003
Doxorubicin 7/13 60 mg/m2 q3wk Levi et al,84 1977
26/30 MF; 1/1 SS 20–40 mg/m2 q2–4wk Wollina et al,85 2003
3/10 20 mg/m2 q4wk Di Lorenzo et al,86 2005
12/13 MF; 1/3 SS; 20 mg/m2 q4wk Pulini et al,87 2007
6/10 MF; 3/5 SS 40 mg/m2 q4wk Quereux et al,88 2008
20/49 20 mg/m2 q2wk Dummer et al,89 2012
Doxorubicin 1 bexarotene 14/34 (Doxorubicin only); 7/15
(doxorubicin 1 bexarotene)
Doxil 20 mg/m2 q2wk; bexarotene 300 mg/m2/d Straus et al,90 2014
Etoposide  cyclophosphamide 2/5 (Etoposide only); 3/4
(etoposide 1 cyclophosphamide)
100 mg/m2 IV  5 d, q2–3wk  cyclophosphamide Molin et al,99 1979
IL-2 3/3 MF; 1/3 SS 20 million units/m2 on d 1–5, 14–17, and 28–30
(induction) followed by 2 d/mo for 5 mo
(consolidation)
Baccard et al,111 1997
5/7 20 million units/m2/d for 5, 4, and 3 d (wk 1, 3, and 5)
followed by optional monthly maintenance  5 d
Gisselbrecht et al,112 1994
4/22 20 million units/m2/d on d 1–4  6 wk in an 8-wk cycle Querfeld et al,107 2007
IL-12 5/10 50, 100, or 300 ng/kg twice weekly, up to 24 wk Rook et al,117 1999
10/23 100 ng/kg twice weekly  2 wk then 300 mg/kg
twice weekly through 24 wk
Rook et al,118 2001
Forodesine 9/13 40–320 mg/m2 BID  4 d in a 16-d cycle Lansigan & Foss,127 2010
10/37 (MF/SS 1 other
T-cell lymphomas)
40–320 mg/m2/d  4 wk Duvic et al,128 2006
11/101 200 mg daily (approximately 80 mg/m2) Dummer et al,129 2014
Bortezomib 7/10 1.3 mg/m2 twice weekly  2 wk in a 3-wk cycle Zinzani et al,133 2007
Abbreviation: TIW, three times weekly.
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Table 2
Combination chemotherapy used in the treatment of mycosis fungoides/Se´zary syndrome
Therapy Regimen
No. of
Patients
Complete
Response D
Partia Response,
n (%)
Complete
Response, n (%)
Median Duration
of Response (mo) Stage Reference
MOPP/COPP 1 TSEB 21 19 (70) 11 (52) 14 I–III Hallahan et al,145 1988; Bunn et al,146 1994
BLM 1 MTX 10 9 (90) 1 (10) 6 T3 Groth et al,147 1979
CHOP/HOP 12 10 (83) 5 (42) 5 II–IV Grozea et al,148 1979; Lamberg et al,149 1979
CHOP/COP 30 9 (30) 3 (10) 6 Not reported Fierro et al,150 1998
CHOP 1 0 0 — T3 Molin et al,151 1980; Raafat & Oster,152 1980
CVP 4 3 (75) 1 (25) Not reported IV Lutzner et al,153 1975
CVP 3 2 (67) 0 (0) Not reported T3 Molin et al,151 1980; Raafat & Oster,152 1980
CVP 16 8 (50) 4 (25) 12 IIB (4), III (1), IV (11) Tirelli et al,154 1986
CVP  TSEB 12 6 (50) 4 (33) Not reported III Hamminga et al,155 1982
CBP 8 5 (63) 2 (25) Not reported Not reported Molin et al,156 1987
CBP 1 retinoid 12 7 (58) 3 (25) Not reported Not reported Molin et al,156 1987
CBP 1 retinoid 20 18 (90) 16 (80) 8 — Zachariae & Thestrup-Pedersen,157 1987
CBP 1 retinoid 1 TF 10 8 (80) 8 (80) Not reported — Zachariae et al,158 1987
CAVOP 5 4 (80) 1 (20) Not reported T3 Molin et al,151 1980; Raafat & Oster,152 1980
COP 1 BLM 12 11 (92) 2 (17) 11.5 II–IV Grozea et al,148 1979; Lamberg et al,149 1979
VICOP-B 25a (84) (36)a 8.7 IIB and IV Fierro et al,96 1997
EPOCH 15 12 (80) 4 (27) 8 IIB–IVB Akpek et al,159 1999
Cyclophosphamide 1
VP-16
4 3 (75) 1 (25) 6 Various, majority T3 Molin et al,99 1979
MBPE 11 8 (73) 1 (9) 6 II–IV Doberauer & Ohl,160 1989
CAVE 52 47 (90) 20 (38) Not reported II–IV Kaye et al,161 1989
TSEB 1 doxorubicin 1
cyclophosphamide
50 49 (98) 44 (88) Range 2–75 I (20); II (20);
III (7); IV (3)
Braverman et al,162 1987
BAM 10 8 (80) 7 (70) 41 IIB–IVB Zakem et al,163 1986
Abbreviations: BAM, bleomycin, adriamycin, and MTX; BLM, bleomycin; BVP, bleomycin, vinblastine, and prednisone; CAVE, cyclophosphamide, adriamycin, vincristine, and etopo-
side; CAVOP, cyclophosphamide, adriamycin, vincristine, VP-16, and prednisone; CBP, cyclophosphamide, bleomycin, and prednisone; COMP, cyclophosphamide, vincristine, MTX,
and prednisone; COP/CVP, cyclophosphamide, vincristine, and prednisone; COPP, cyclophosphamide, vincristine, procarbazine, and prednisone; MBPE, MTX, bleomycin, prednisone,
and etoposide; MOPP, meclorethamine, vincristine, procarbazine, and prednisone; TF, transfer factor; TSEB, total skin electron beam therapy.
a Includes a cohort of patients with pleomorphic lymphoma.
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Chemotherapeutic Agents in CTCL 791and ribonucleotide reductase, thus inhibiting both
DNA and RNA synthesis. It is unclear which of
these play a more important role in cytotoxicity,
or if both do.
6-Mercaptopurine
6-Mercaptopurine (6-MP or Purinethol) is an oral
thiopurine used in acute lymphocytic leukemia. It
has not been studied in MF/SS and is not recom-
mended in the National Comprehensive Cancer
Network (NCCN) guidelines for NHL.3
Fludarabine
Fludarabine (Fludara) is an adenosine analog that
inhibits adenosine deaminase, leading to an accu-
mulation of deoxyadenosine triphosphate, which
in turn inhibits DNA polymerase and ribonucleotide
reductase. It can be given both orally (available in
Canada but not in the United States) and intrave-
nously (IV). It is FDA approved for use in chronic
lymphocytic leukemia (CLL) and is also used as a
component of multiagent chemotherapy for NHL.
As a single agent, fludarabine at 18 to 25 mg/m2
for 5 days every 3 to 4 weeks was modestly effec-
tive in advanced-staged MF with an overall res-
ponse rate (ORR) of 26% (21/80 patients)
between three trials [2/5 (40%)] of patients with
MF (Redman and colleagues4), stage not other-
wise reported; 6/31 (19%) evaluable patients with
stage IB–IVB MF (Von Hoff and colleagues)5; and
13/44 (29.5%) patients with stage IIB–IV MF (Qua-
glino and colleagues).6 Fludarabine has been used
in combination with IFN (5–7.5 million units/m2
3 times a week)7 in 35 patients with MF, 31 who
had stage IV disease, with an ORR of 51%. Fludar-
abine has also been used in combination with
cyclophosphamide (250 mg/m2  3 days every
4 weeks  3–6 months)8 in 12 patients with stage
III–IVA MF/SS, with an ORR of 42%. The duration
of response was low.
Given its modest benefit and significant side
effects of myelosuppression and immunosuppres-
sion with lymphocyte dysfunction that persists
beyond treatment, fludarabine has a limited role
in the treatment of MF/SS outside of its role in con-
ditioning regimens for stem cell transplant. Addi-
tional side effects include dose-dependent
neurotoxicity, gastrointestinal (GI) symptoms, and
pulmonary toxicity.2 Secondary neoplasms have
also been reported.
Cladribine
Similar to fludarabine, cladribine (2-chlorodeoxya-
denosine, 2-CdA, or Leustatin) is an adenosine
analog that inhibits DNA and RNA synthesis
through its interaction with adenosine deaminase.
Due to the high concentration of adenosine
deaminase in T lymphocytes, cladribine actspreferentially in this cell population. It is FDA
approved for hairy cell leukemia. In 1 of several
early studies, 2 of 2 patients (stages not reported)
treated with cladribine, 0.1 mg/kg/d for 7 days
every 4 weeks, had a partial response (PR).9
O’Brien reported on a complete response (CR) in
1/8 patients with stage I–IV MF treated with cladri-
bine, 4 mg/m2/d for 7 days every 28 days.10 Kuzel
and colleagues11 performed a phase II study
examining 0.1 mg/kg/d for 5 to 7 days and
reported an ORR of 28%, including 3 with a CR
(3/4 stage IB, 0/2 stage IIB, 2/5 stage III, 1/8 stage
IVA, and 0/2 stage IVB). Low-dose cladribine,
0.06 mg/kg/d  5 days every 4 weeks for up to 8
cycles, has been shown to provide some palliation
(1/2 stage IIB and 1/6 stage IVA ORR).12
Similar to fludarabine, cladribine causes myelo-
suppression and protracted lymphopenia, with a
decrease in CD4/CD8 ratio that can last 6 to
9 months after treatment.2 Given the high degree
of immunosuppression associated with advanced
MF/SS,13 this side effect limits the use of cladri-
bine in MF/SS.
Pentostatin
Pentostatin (deoxycoformycin or Nipent) also in-
hibits adenosine deaminase, leading to a block in
DNA synthesis. It is FDA approved for use in hairy
cell leukemia. In one of the larger studies to
examine pentostatin in advanced-stage (IIB or
higher) disease, there was an ORR of 56% among
32 patients.14 Dosing was 5 mg/m2 for 3 days
every 3 weeks. In an Eastern Cooperative
Oncology Group (ECOG) study of 8 patients with
CTCL (stages not reported), 4 of 8 had a
response.15 Dang-Vu and colleagues16 reported
on 1 patient with stage IIA MF treated with
5 mg/m2/d for 3 days repeated at 35- to 71-day in-
tervals who had a CR that lasted greater than
16 months off therapy. In a study by Greiner and
colleagues17 in 18 patients with stage I–IVB using
4 to 5 mg/m2 every 1 to 4 weeks, there was an
ORR of 39% (0/1 stage IA, 3/4 stage IIA, 1/3 stage
IIB, 1/3 stage III, 2/6 stage IVA, and 0/1 stage IVB),
including 2 CRs, with a median number of 5 cycles.
In a study performed by the European Organisa-
tion for Research and Treatment of Cancer
(EORTC), 22 patients with MF with lymphadenop-
athy or organomegaly and 21 patients with SS
treated with pentostatin demonstrated 23% (5/22
patients) and 33% (7/21 patients) ORR, respec-
tively.18 Dosing in this trial was 4 mg/m2 weekly
for 3 weeks followed by every other week for
6 weeks. There was a monthly maintenance phase
for 6 additional months at 4 mg/m2. In a dose-
adaptable study with a starting dose of 5 mg/m2,
Kurzrock and colleagues.19 reported a response
Chung & Poligone792in 70% of 20 patients (10/14 SS and 4/6 tumor
stage). Pentostatin (days 1 and 3 at 4 mg/m2)
has been combined with IFN (days 22 and 50 at
10 million units/m2 and days 23 through 26 at 50
million units/m2) in a phase II study of 41 patients
(2 stage I–IIA, 5 stage IIB/III, 27 stage IVA, and 7
stage IVB) that showed an ORR of 41%.20
Response in the blood, as defined by at least a
50% reduction in circulating atypical cells, was
seen in 8 of 24 patients with blood involvement.
None of the 7 patients with IVB (visceral involve-
ment) had a response.
One retrospective study of 8 patients examined
the use of pentostatin (4 mg/m2 every 2 weeks)
plus bexarotene (150 mg/m2  14 days followed
by 300 mg/m2  14 days) plus cyclophosphamide
(600 mg/m2 every 2 weeks) for up to 8 cycles.21 A
median of 4 cycles was completed, with only 3 pa-
tients completing all 8 cycles. The response rate
was 88% (1/1 stage IIA, 1/1 stage IIB, 2/2 stage
III, 1/1 stage IVA, and 2/3 stage IVB); 5 patients
demonstrated a CR, including the 2 patients with
stage IVB. Unlike many prospective trials in MF/
SS, however, most patients in this study had not
been heavily pretreated (or were entirely treatment
naı¨ve).
Pentostatin can cause hematologic side effects,
including a prolonged depression of CD4 count.2
The bone marrow suppression with pentostatin
typically occurs, however, in the initial cycles and
is not as prolonged as observed with other adeno-
sine deaminase inhibitors. GI distress, fevers, and
transient liver function test abnormalities may also
occur. Neurologic and pulmonary side effects
have also been reported.2
Pyrimidine Analogs/Antagonists
Pyrimidine analogs are antimetabolites with a
chemical structure that mimics pyrimidine bases
(uracil and cytosine). Both DNA and RNA synthesis
are inhibited, although similar to the purine ana-
logs, it is uncertain which mechanism is most
important in cytotoxicity and cell death.
5-Fluorouracil
5-Fluorouracil (5-FU or Adrucil) is an antimetabo-
lite that mimics uracil and inhibits DNA synthesis
through irreversible inhibition of thymidylate syn-
thase.22 There are few data on the use of IV 5-FU
in the treatment of lymphoma. One study of 10 pa-
tients (1 stage IIA, 4 stage IIB, 1 stage III, 2 stage
IVA, and 2 stage IVB) who were treated sequen-
tially with methotrexate (MTX) (60–120 mg/m2) fol-
lowed by 5-FU (20 mg/kg per 24 hours for
36 hours) and leucovorin showed response in all
patients treated.23 Themedian survival for patients
with tumors, regardless of stage, in this study was5.25 years, compared with 3.3 years for patients
not treated with this regimen.24 There has been lit-
tle follow-up, however, regarding these preliminary
findings.
In a similar fashion, topical 5-FU has been re-
ported to be of benefit in some patients with MF.
Zackheim and Farber25 considered the use of
topical antimetabolites for the treatment of skin
lymphoma more than 40 years ago. Only 1 trial
with 6 patients (4 stage IA, 1 stage IB, and 1 stage
IIB) has examined the use of topical 5-FU in MF/SS
thus far. After daily topical treatment with 5-FU for
3 to 18 months, all 6 patients demonstrated a
response.26
Cytosine arabinoside
Although there are data supporting the use of
cytosine arabinoside (cytarabine or ara-C) in
some NHLs, there are no data supporting its use
in MF/SS. It is not recommended in the NCCN
guidelines for treatment of CTCL.
Gemcitabine
Gemcitabine (20,2’-difluorodeoxycytidine or Gem-
zar) is a pyrimidine nucleoside analog that mimics
deoxycytidine. It is phosphorylated intracellularly
and inhibits DNA synthesis. Gemcitabine is unique
among the pyrimidine analogs in that it inhibits its
own deamination (through interference of deoxy-
cytidylate deaminase), thereby prolonging its ac-
tivity.27 It is FDA approved for use in breast,
ovarian, lung, and pancreatic cancer. In a phase
II study of 30 patients with stage T3 or T4,N0,M0
MF who had failed previous systemic therapy
and were treated with 1200 mg/m2 days 1, 8,
and 15 monthly  3 months, there was a 70%
response rate.28 In a follow-up from 1 of the cen-
ters in this study, Zinzani and colleagues reported
on 19 patients with T3 or T4,N0,M0 MF who were
followed for up to 10 years after treatment with
gemcitabine (3–6 cycles at 1200 mg/m2/d on
days 1, 8, and 15 of a 28-day cycle). There was
an ORR of 48% with a disease-free interval of
10, 18, and 120 months in 3 patients with a CR.
In a multicenter phase II study of 26 patients with
untreated MF/SS with advanced-stage disease
(T3 or T4,N0,M0) treated with gemcitabine at
1200 mg/m2 on days 1, 8, and 15 of a 28-day cycle
for 6 cycles, an ORR of 73% was observed.29
There was 1 patient in this trial with SS and that pa-
tient did not have a response.29
In another phase II study of gemcitabine in pa-
tients with MF, primarily stage IIB or greater,
treated with 1000 mg/m2 on days 1, 5, and 8 of
a 28-day cycle, 20 of 31 (65%) had a response.
Among those patients with stage IVA and IVB
having B2 blood involvement (SS), 8 of 11
Chemotherapeutic Agents in CTCL 793patients responded.30 A retrospective study of 14
patients with MF with T3 or T4 disease (11 were
transformed) and 6 patients with SS at 4 centers
treated with 1000 mg/m2 (with various schedules)
showed 78% ORR in MF and 50% ORR in SS.31
In a separate study, 3 patients with refractory
tumor-stage MF demonstrated a response to
gemcitabine, administered at 1000 mg/m2 for
multiple cycles, which was then decreased to
250 mg/m2 weekly.32 In all 3 patients, there was
eventual progression of lymphoma within
4 months of stopping therapy (including 1 case
with meningeal involvement), suggesting that
low-dose gemcitabine is not useful as a mainte-
nance therapy. These findings are in contrast to
a separate case series reporting that 4 of 8
patients with refractory MF who had a response
with lower-dose gemcitabine (150 mg/m2).30
The role of lower-dose gemcitabine in main-
tenance therapy requires further exploration.
Finally, in a trial that combined gemcitabine,
1000 mg/m2 IV on days 1 and 8 of a 21-day cycle
for 4 cycles, with bexarotene, 300 mg/m2 daily in
35 patients with MF/SS (5 stage IB, 2 stage IIA, 8
stage IIB, 8 stage III, and 12 stage IVA), the
combination was not superior to gemcitabine
alone.33
More common side effects of gemcitabine
include elevations in liver function tests and bone
marrow suppression with anemia, thrombocyto-
penia, and/or leukopenia. Other side effects
include pulmonary toxicity, hemolytic uremic syn-
drome, exacerbation of radiation toxicity, capillary
leak syndrome, hyperpigmentation, and posterior
reversible encephalopathy,2,34 all of which are
rare.
Antifolates
Pralatrexate and MTX are discussed in the article
by Wood and Wu elsewhere in this issue.
ALKYLATING AGENTS
Alkylating agents in chemotherapy were devel-
oped after it was noted that people exposed to
the military agent, mustard gas, developed
bone marrow suppression and lymphopenia. Ni-
trogen mustard was a less toxic agent that
showed efficacy in various lymphomas.35 There
are 6 types of alkylating agents: (1) nitrogen mus-
tards, (2) nitrosoureas, (3) alkyl sulfonates, (4) tri-
azines, (5) ethylenimines, and (6) metal salts. The
cellular enzyme O6-methylguanine–DNA methyl-
transferase (MGMT) is able to repair the cyotoxic
damage caused by alkylating agents, thereby
introducing a mechanism for resistance to these
compounds.Nitrogen Mustards
Mechlorethamine
Mechlorethamine (Mustargen) is an alkylating
agent that is currently infrequently used in a sys-
temic form in the treatment of MF and SS. Karnof-
sky36 and Van Scott and colleagues37 reported 21
and 41 cases of MF/SS, respectively, treated with
systemic nitrogen mustard. Karnofsky noted
some benefit in the first cycle but later cycles
were less effective.36 Van Scott treated 46 pa-
tients with advanced cutaneous lymphomas,
including 41 with MF or SS, with systemic Mustar-
gen at various dosing regimens along with topical
nitrogen mustard and reported a decrease in
stage of disease in 34/41 MF/SS patients,
including 12/41 (29%) with a CR.37 These results
with systemic nitrogen mustard ultimately led to
the use of topical nitrogen mustard in the treat-
ment of MF/SS.
Lymphopenia due to systemic mechlorethamine
is common. Additional side effects include alope-
cia, tinnitus, nausea, vomiting, hypersensitivity,
skin eruptions, and damage to reproductive or-
gans/infertility. Thrombosis and thrombophlebitis
may occur when the drug is infused IV.Chlorambucil
Developed from nitrogen mustard, chlorambucil
(Leukeran) is an alkylating agent that prevents
DNA replication by cross-linking DNA, leading to
DNA strand breaks. Chlorambucil was one of
the first systemic treatments recognized to have
activity specifically in SS38,39 and since that
time, there have been multiple case reports/se-
ries suggesting benefit in this setting.40–42 Win-
kelmann developed the Winkelmann method,
which consists of oral chlorambucil (2–6 mg/d)
with prednisone (10–20 mg/d, weaned over
time) for the treatment of SS.39,43–45 It has also
been adapted for the treatment of CLL, where it
continues to be a common therapy.45 Winkel-
mann reported that SS patients lived twice as
long with chlorambucil therapy and 10 of 17 pa-
tients had a decreased peripheral blood Se´zary
cell count. Seven of 19 SS patients had a CR
for at least 1 year on chlorambucil/corticoste-
roid.44 Coors and colleagues43 used chlorambucil
with corticosteroids (chlorambucil 10–12 mg for
3 days and fluocortolone, first day 75 mg, second
day 50 mg, and third day 25 mg) twice monthly
and reported a 100% ORR in 13 patients with er-
ythrodermic disease (8 stage III, 4 stage IVA, and
1 stage IVB). Moreover, a significant improve-
ment in pruritus was also reported. McEvoy and
colleagues46 described 11 patients treated with
combined chlorambucil-prednisone using the
Chung & Poligone794Winkelmann method and adding leukapheresis
with an ORR of 100%.
Lower doses of chlorambucil as utilized in the
Winkelmann method are well tolerated. Leuko-
penia can occur and requires monthly blood
counts.2 Less common side effects include bone
marrow suppression (thrombocytopenia, anemia,
and leukopenia), drug fever, and hyperuricemia,
which often occur soon after starting therapy.
Additionally, because some patients remain on
chlorambucil for longer periods of time, it is impor-
tant to be aware of the delayed side effects, which
include amenorrhea, azospermia, infertility, pul-
monary interstitial fibrosis, cystitis, hepatotoxicity,
and peripheral neuropathy. These toxicities are
consistent among other alkylating agents.
Although in a past, study doses above 1300 mg
of chlorambucil were found leukomogenic,47
more recently the risk of secondary malignancy
in NHL after chlorambucil treatment was not found
significant.48
Ifosfamide
Ifosfamide is an alkylating agent that has been
combined with other chemotherapies in the treat-
ment of NHL. It is part of ifosfamide, carboplatin,
and etoposide (ICE) and ifosfamide and etoposide
(IFE) multiagent chemotherapy. Although there are
no data on its use in MF/SS, it has been reported
(multiagent ICE regimen) in the treatment of non-
MF CTCL.49 It is also used as a second-line agent
for aggressive T-cell lymphomas.50
Bendamustine
Bendamustine (Treanda) is a nitrogen mustard al-
kylating agent. Its chemical structure also makes
it a purine analog.51 This diversity in structure
may explain why it is effective in a diverse range
of cancers, including CLL52; multiple myeloma53;
solid tumors, including breast and lung can-
cer54,55; and NHL.56,57 It has a different antitumor
effect than other alkylating agents (including
cyclophosphamide, chlorambucil, or melphalan)
and seems to function not only as an alkylating
agent causing DNA breaks but also through ef-
fects on transcription and posttranslational
events.51 Bendamustine’s structure and diversity
of mechanism of action may make it less suscep-
tible to drug resistance than other alkylating
agents.51 It is FDA approved for the treatment of
indolent NHLs and CLL. Bendamustine, 120 mg/
m2/d over 30 to 60 minutes on days 1 and 2 every
3 weeks, for a total of 6 cycles, demonstrated
benefit in T-cell lymphomas in an early phase II
trial. This trial only included 2 MF patients (stage
not defined) who were not analyzed as a sub-
group. The ORR in the study (with most patientshaving peripheral T-cell lymphoma [PTCL]) was
50% (30 of 60 patients).58 In a second trial that
enrolled 3 patients with advanced-stage MF/SS,
there were 2 with a PR at monotherapy doses of
60 to 100 mg/m2.59 The nonresponder, however,
only received 1 cycle of bendamustine.
Myelosuppression requiring granulocyte
colony-stimulating growth factors frequently oc-
curs. Other hematologic abnormalities are also
common, including lymphopenia, anemia, and
thrombocytopenia. Infections, infusion reactions,
and severe skin reactions, including toxic
epidermal necrosis, have been reported. There
are also reports of severe cytomegalovirus reac-
tivation with treatment.60 The most common non-
hematologic side effects are nausea and
vomiting.
Cyclophosphamide
Cyclophosphamide (Cytoxan) is an alkylating
agent and derivative of mechlorethamine. Similar
to other alkylating agents, it induces double-
strand breaks in DNA. Although multiple studies
have shown that single-agent cyclophosphamide
has activity against MF/SS, the benefit is often
low.61–66 Abele and Dobson61 reported 4 cases,
mostly with early-stage disease, who showed a
response. Van Scott and colleagues66 subse-
quently reported 11 more cases, with 5 patients
responding to single-agent cyclophosphamide at
50 to 300 mg/d for up to 117 days. Patients were
treated until they developed leukopenia or anemia.
There are multiple dose-limiting toxicities. Hemor-
rhagic cystitis, risk to reproductive capacity, and
total alopecia are additional issues. Currently,
single-agent cyclophosphamide is uncommonly
used. As part of multiagent regimens (eg, CHOP),
it remains a commonly used drug in MF/SS (see
Table 2).
Melphalan
Melphalan (phenylalanine mustard, L-PAM, or Al-
keran) is an alkylating agent and not used in the
primary treatment of MF/SS but is used in combi-
nation in some conditioning regimens during stem
cell transplantation.67–69 This is discussed in the
article by Virmani and colleagues elsewhere in
this issue.
Lomustine
Lomustine (CeeNU) is an alkylating agent that is
approved by the FDA for the treatment of brain tu-
mors and Hodgkin lymphoma. It has not been
studied in MF/SS but has been reported to have
activity in 2 Tasmanian devils, 1 ground cuscus,
and frequently in dogs with CTCL.70–72 It is not rec-
ommended in the NCCN guidelines for treatment
of NHL.
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Similar to carmustine (BCNU), nimustine (ACNU or
Nidran) has activity against MF, although the level
of activity has been relatively undefined. It is not
FDA approved for any use.73Nitrosoureas
Carmustine
Carmustine is used IV for some lymphomas but
not for MF/SS. It is compounded for topical
application.Alkyl Sulfonates
Busulfan
Busulfan (Busulfex or Myleran) is not used in the
primary treatment of MF/SS but is used in combi-
nation in some conditioning regimens during stem
cell transplantation.67–69Triazines
Dacarbazine
Dacarbazine (DTIC or DTIC-Dome) is an alkylating
agent that is not used as a single agent in MF/SS
but is part of the doxorubicin, bleomycin, vin-
cristine, and dacarbazine (ABVD) multiagent
chemotherapy, a first-line therapy for Hodgkin
lymphoma. Its benefit in MF/SS has not been
established.
Temozolomide
Temozolomide (TMZ or Temodar) is an oral
alkylating agent and a derivative of dacarbazine
that is FDA approved for the treatment of certain
brain cancers. In several small studies it has
been shown to have activity in MF/SS. One
patient with advanced MF was part of a study
of 42 patients examining TMZ therapy for
advanced cancer. The patient had a CR that
lasted 7 months.74 In a study of 9 patients with
stage IIB or III MF, there was an ORR of 33%
(3 of 9).75 In the most recent trial, which ex-
amined TMZ at 200 mg/m2 for 5 days every
28 days in stage IB–IVA MF/SS, there was
an ORR in 7 of 26 (27%) in patients with treat-
ment refractory disease.76 Response was as-
sessed at the 2nd cycle and responders were
treated with TMZ through 1 year. The median
disease-free survival, however, was only
4 months.
Myelopsuppression is common and requires
dose reduction. The drop in neutrophils commonly
occurs on day 22 after the initial dose. Nausea,
vomiting, hepatotoxicity, and infections can also
occur. Prophylaxis for pneumocystis pneumonia
is required.Procarbazine
Procarbazine (Matulane) has not been reported in
the primary treatment of MF/SS but is used in
certain multiagent regimens, such as MOPP (see
Table 2).
Ethylenimines
Thiotepa
Thiotepa (Thioplex) is not used in the primary treat-
ment of MF/SS but is used in combination in some
conditioning regimens during stem cell
transplantation.67–69
Metal Salts
Carboplatin
Carboplatin (Paraplatin) is not used in the primary
treatment of MF/SS but is used in multiagent ICE
therapy. ICE is generally reserved, however, for
use only in transformed MF/SS as a second-line
therapy.50
Cisplatin
Cisplatin (Platinol) is not used in the primary treat-
ment of MF/SS but is used in multiagent (eg, eto-
poside, methyprednisilone, cytarabine, cisplatin
[ESHAP]) therapy. ESHAP is generally reserved,
however, for use only in second- or third-line
salvage therapy in transformed MF/SS. Moreover,
its risk/benefit has been questioned by a past
study in patients with aggressive CTCL, which
included 1 SS and 1 MF patient, due to high recur-
rence and low duration of response.77 There was 1
PR in the MF patient, but that patient demon-
strated disease progression within 2 months.
TOPOISOMERASE INHIBITORS
Anthracyclines
Anthracyclines were first developed from a com-
pound found in the soil bacteria Streptomyces.78
They are 1 of the most important class of drugs
in the treatment of hematologic cancers79 and
work mainly by DNA intercalation and inhibition
of topoisomerase II.80 Although there is a strong
antitumor effect, cardiotoxicity has been a com-
mon side effect that has historically limited use.
Newer delivery systems that involve liposome
encapsulation prolong the half-life of drug in cir-
culation and alter the biodistribution such that
there is increased deposition in tumor tissue
with decreased deposition in normal tissues,
with resultant decreased toxicity.81–83 Pegylation
additionally improves pharmacodynamics and
pharmacokinetics of the drug. These formula-
tions with decreased cardiotoxicity have allowed
anthracyclines to be important agents in the
treatment of MF/SS.
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doxorubicin
Doxorubicin (AAN, hydroxydaunorubicin, or
Adriamycin) is currently the most commonly
used anthracycline for advanced CTCL. It is
used for the treatment of NHL as part of the
CHOP regimen. It is also FDA approved for the
treatment of HIV-related Kaposi sarcoma. Doxo-
rubicin monotherapy in MF was first reported by
Levi and colleagues in 1977.84 Thirteen patients
with MF (described as “advanced disease,”
including 10 with tumors, 8 with lymph node
involvement, and 4 with visceral involvement)
were treated with a single IV dose of 60 mg/m2,
repeated in 21-day intervals, and continued for
3 doses beyond maximum clinical response for
those who achieved remission. The investigators
reported an ORR of 85%, including 23% CR. One
patient with preexisting heart disease experi-
enced cardiotoxicity with fatal congestive heart
failure. In a dose-escalation study with pegylated
liposomal doxorubicin (Doxil or Caelyx), Wollina
and colleagues85 reported 30 patients with stage
I–IV MF and 1 patient with SS treated with 20 to
40 mg/m2 1 to 2 times monthly; 26 of 30 patients
with MF and the 1 patient with SS achieved a PR
with an ORR of 87%, including 43% CR. Di Lor-
enzo and colleagues86 reported on 10 patients
with stage IVB MF treated with pegylated lipo-
somal doxorubicin 20 mg/m2 IV every 4 weeks.
Unlike the patients in Wollina and colleagues’
study, no subjects were noted to have a CR; 3 pa-
tients experienced a PR with an ORR of 30%. The
investigators attribute the difference in response
between the 2 studies to the fact that those in
the latter study were characterized uniformly by
advanced-stage disease. In a multicenter phase
II trial with pegylated liposomal doxorubicin,87
19 patients, including 16 patients with MF/SS
and 3 with PTCL, were treated with 20 mg/m2
every 4 weeks for 2 to 8 treatments. The investi-
gators reported an ORR of 81.2% (13/16) in the
MF/SS patients, including a CR in 1 of 4 patients
with stage I–IIA MF, 6 of 9 patients with stage IIB–
IV MF, and 1 of 3 patients with SS. In another
study with 25 patients with stage IIB–IVB MF
and SS, subjects were administered pegylated
liposomal doxorubicin at 40 mg/m2 monthly for
8 cycles.88 There was an ORR of 56%, with 5 pa-
tients achieving CR and 9 patients achieving PR.
Of patients with SS, 1 had CR and 5 experienced
PR. In those patients who responded, a median
progression-free survival (PFS) of 5 months was
observed. In an EORTC-initiated phase II trial
for pegylated liposomal doxorubicin, Dummer
and colleagues89 studied a cohort of 49 patients
with stage IIA–IVB MF from 9 centers in 6countries. The patients were treated with
20 mg/m2 IV on days 1 and 15 every 28 days (1
cycle) for up to 6 cycles. The ORR was 40.8%,
including 3 patients with CR and 17 patients
with PR. PFS was approximately 6 months in
those who responded. In 2014, Straus and col-
leagues90 published results of a phase II trial us-
ing doxorubicin hydroxychloride liposome
injection in 37 patients with stage IB–IV disease,
including 10 patients with SS. Subjects were
treated with 20 mg/m2 IV every 2 weeks for
16 weeks. All patients who did not progress
also received bexarotene, 300 mg/m2 daily, start-
ing at week 16 for an additional 16 weeks; 41%
responded with a CR observed in 2 patients
(both stage IV) and a PR in 12 patients. The me-
dian overall survival duration was 18 months;
there were 22 deaths after discontinuation of pro-
tocol treatment.
As discussed previously, cardiotoxicity may
occur with doxorubicin, the risk of which may be
reduced by limiting the cumulative dose to 450
to 550 mg/m2.91 Additional side effects include
dose-dependent hematologic toxicity (including
severe neutropenia), GI symptoms, palmoplantar
erythrodysesthesia, and alopecia.
Daunorubicin and liposomal daunorubicin
Similar to doxorubicin, daunorubicin (daunomycin
or Cerubidine) is a topoisomerase inhibitor anthra-
cycline.78 Although there has been more utilization
of liposomal doxorubicin in MF/SS, liposomal
daunorubicin (DaunoXome) also has shown activ-
ity in MF/SS. In a case series of 3 patients with tu-
mor stage MF receiving liposomal daunorubicin, at
20 to 40 mg/m2 once every 3 to 4 weeks, all 3 pa-
tients responded.92
Liposomal daunorubicin is FDA approved for the
treatment of advanced HIV-associated Kaposi
sarcoma. Myelosuppression, infections, alopecia,
neuropathy, and cardiotoxicity occur, although
grade 3 and 4 reactions are less common.
Epirubicin (Ellence)
The anthracycline, epirubicin (Ellence), is compa-
rable to doxorubicin and has been described in a
multiagent regimen similar to CHOP but without
vincristine.93 In the patient reported, however,
who had stage IB disease, skin-directed therapies
are standard and not multiagent chemotherapy.
Several other cases with modified CHOP regimens
have also been described replacing epirubicin for
doxorubicin.94,95 It is currently not known if epiru-
bicin has any advantage over doxorubicin in multi-
agent regimens for MF/SS. Moreover, foregoing
vincristine is not known to be significantly safer
or superior to standard CHOP.
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Idrarubicin (4-demethoxydaunorubicin or Idrarubi-
cin) is an anthracycline approved by the FDA for
the combination treatment of acute myeloid
leukemia in adults. It is currently not known if idrar-
ubicin has any advantage over doxorubicin in the
treatment of MF/SS. It has been reported in com-
bination with etoposide, idarubicin, cyclophos-
phamide, vincristine, prednisone, and bleomycin
(VICOP-B) in advanced MF, but there were no re-
sponses observed in SS96 (see Table 2).Etoposide
Etoposide (VP-16, VP-16-213, or epipodophyllo-
toxin) is a semisynthetic derivative of podophyllo-
toxin, a plant toxin. It is FDA approved for small
cell lung cancer, treatment of testicular tumors,
and part of combination chemotherapy regimens
for hematologic malignancies. It is available in
both oral and IV formulations. Etoposide functions
primarily via reversible binding to DNA topoisom-
erase II, which results in the inability of this enzyme
to repair double-stranded DNA breaks and subse-
quent cell death. Additionally, it induces single-
strand and double-stranded DNA breaks.2
Etoposide as monotherapy in MF/SS is not well
studied and consists predominantly of single case
reports. Jacobs and colleagues,97 in 1975, re-
ported a patient with tumor-stage MF who experi-
enced CR to etoposide, 60 mg/m2 IV for 5 days,
given every 2 weeks. The total duration of treat-
ment was not reported. The investigators also re-
ported a second patient98 with stage III MF who
achieved CR with the same induction regimen for
a total of 5 infusions, followed by monthly mainte-
nance courses of 60 mg/m2 IV and oral etoposide
100 mg/m2 twice weekly for 3 weeks. Molin and
colleagues99 treated 9 patients with MF/SS (1/9
plaque stage and 8/9 tumor stage) with etoposide,
100 mg IV daily 5 days every 2 to 3 weeks induc-
tion therapy, followed by 100 mg daily  5 days
during maintenance. Four of these patients also
received concomitant cyclophosphamide. CR
occurred in 2 patients and PR in 3; of these, 1
CR and 1 PR were treated with single-agent eto-
poside. In all responders, disease progression
eventually occurred after 4 to 6 months. Nasuhara
and colleagues100 described a patient with MF
with pulmonary involvement who experienced
CR of over 2 years’ duration with oral etoposide,
200 mg weekly, and prednisolone. He had previ-
ously been treated with combination chemo-
therapy with CHOP without any impact on skin
lesions. Onozuka and colleagues101 reported a pa-
tient with stage III MF treated with 150 mg IV, 3
times per week for 9 weeks, followed by oraletoposide, 25 mg daily for 21 days every 4 weeks;
this therapy was continued for 60 months, 36 of
which he experienced CR. Miyoshi and Noda102
described a patient with SS (criteria not defined)
who experienced CR for 4 years with oral etopo-
side; the dose used was not specified, however.
Hirayama and colleagues103 also reported a pa-
tient with SS who experienced CR with etoposide
therapy; he was administered 25 mg orally with
concomitant MTX of 10 mg weekly, with response
maintained for 4 years.
Etoposide is generally well tolerated. Side ef-
fects predominantly involve myelosuppression
and may be dose limiting. Other adverse effects
include GI symptoms (nausea and vomiting), mu-
cositis, and alopecia.2 Chronic etoposide therapy
has also been associated with acute myeloid leu-
kemia. This complication has been reported 15
to 100 months after initiation of therapy, with
increased risk associated with total cumulative
dose as well as increased treatment frequency
(ie, weekly or twice-weekly therapy compared
with alternate week therapy).102,104,105INTERLEUKINS
Interleukin-2
Interleukin (IL)-2 (aldesleukin or Proleukin) is a
15-kD polypeptide produced by activated CD41
lymphocytes. Overall, IL-2 stimulates activation,
proliferation, and maintenance of T-helper lym-
phocytes in vivo and in vitro.106 Although its anti-
tumor effects are not well understood, they have
been observed in various tumors. In MF/SS, IL-2
is thought to prevent and control disease progres-
sion through a favorable influence on cytokine
milieu, including T-helper cytokine balance in im-
mune responses.107 IL-2 is FDA approved for the
treatment of metastatic renal cell carcinoma and
metastatic melanoma.
Nagatani and colleagues108 first reported the
successful treatment of a patient with tumor-
stage MF treated first with intralesional IL-2 and
then systemic IL-2 monthly. He maintained CR
for 13 months. Rybojad and colleagues109 re-
ported a patient with stage IIB MF with a cytotoxic
immunophenotype (CD81 and CD4) post–total
skin electron beam radiation and autologous
bone marrow transplant who underwent induction
therapy with IL-2 IV infusion of 10 million units/
m2/d for 5, 4, and 3 consecutive days every
2 weeks followed by 5 monthly maintenance
courses of 10million units/m2/d for 2 days. The pa-
tient achieved a CR and remained without evi-
dence of disease 10 months after discontinuation
of therapy. Marolleau and colleagues110 evaluated
3 patients with MF and 3 with SS treated with IV
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and 28 to 30 (induction) followed by 2 days per
month for 5 months (consolidation). At the end of
consolidation, 2 of 3 patients with MF (stages
IIB–IVA) experienced a CR; a PR was seen in 1
of 3 SS patients. In a follow-up letter, it was
observed that 2 of the patients with a CR
continued to have response at 56 and 63 months
post-treatment.111
Gisselbrecht and colleagues112 performed a
phase II study with 5 patients with MF (all stage
IV) and 2 patients with SS treated with IV infusions
of 20 million units/m2/d for 5, 4, and 3 days on
weeks 1, 3, and 5 followed by an optional monthly
maintenance therapy of 5 days. One patient had
CR and 4 had a PR with an ORR of 71%. The pa-
tient with CR had a continued response for
29 months after initial response. In a phase II study
using subcutaneous injections, Querfeld and col-
leagues107 evaluated 22 patients with MF. Eleven
MUs were injected for 4 consecutive days per
week  6 weeks followed by 2 weeks’ observation
and repeated for 8 weeks as tolerated. Only 4 pa-
tients responded (18%; 1/1 stage IA, 1/6 stage IB,
0/1 stage IIA, 1/3 stage IIB, 1/4 stage III, and 0/7
stage IVA/SS) and no CR was noted. The median
event-free survival was 3 months.
Side effects include flulike illness (fever, chills,
and fatigue), GI symptoms (nausea and vomiting),
weight gain, elevated creatinine, hypotension, cy-
topenia, vascular leak syndrome, neurologic
symptoms, and cardiac toxicity.2,107,110Interleukin-12
IL-12acts asapotent inducer of IFN-gbyTcells and
natural killer cells and directly stimulates cytotoxic
T-cell activity.106,113 In advanced stages of CTCL,
peripheral blood dendritic cells (which are pro-
ducersof IL-12) aredepleted innumber and function
with a concomitant decrease in IL-12 produc-
tion.106,114–116 Additionally, diminished IL-12 levels
mayoccurdue to increased IL-10productionbyma-
lignant T cells.113 Recombinant human IL-12 has
beenevaluated in the treatmentofMF/SS.Currently,
there are no FDA-approved uses for IL-12.
In a phase I dose-escalation trial, 7 patients with
MF (2 with T1, 3 with T2, 2 with T3, 2 with T4 skin
stages, and 3 with SS) received 50, 100, or 300 ng/
kg of IL-12 subcutaneously twice weekly for up to
24 weeks.117 Each patient with T3 disease
received the injections directly into tumor lesions.
The ORR was 56% with 2 patients achieving CR
(both T2) and 3 with PR (2 with T1 skin stage and
1 SS). In patients with tumors, there was flattening
and/or resolution of the tumors treated intralesion-
ally, but new lesions developed at other sites. In aphase II trial, Rook and colleagues118 evaluated 23
patients with stage IA–IIA MF treated with subcu-
taneous IL-12 100 ng/kg twice weekly  2 weeks
with subsequent increase to 300 ng/kg twice
weekly for up to 24 weeks.119 There was an ORR
of 43% (10/23), all of which were PRs. Although
no CRs were observed, many of those with a PR
had extensive clearing of skin lesions.
Adverse effects of IL-12 are generally mild and
short lived. These include fatigue, headache, my-
algias, injection site reaction, neutropenia, diar-
rhea, depression, and anxiety.113,117–119 One
death from autoimmune hemolytic anemia has
been observed,119 but it was unclear if this was
directly due to IL-12 administration or secondary
to an infection.PURINE NUCLEOSIDE PHOSPHORYLASE
INHIBITORS: FORODESINE
Purine nucleoside phosphorylase (PNP) catalyzes
phosphorolysis of deoxyguanosine to guanine
and ribose 1-phosphate120,121 Inhibition of PNP
in T lymphocytes results in the accumulation of de-
oxyguanosine triphosphate, which in turn inhibits
DNA synthesis with resultant suppression of cell
proliferation.121,122 Selective T-cell depletion oc-
curs with PNP inhibition due to a relatively high
level of kinase and low level of nucleotidase activ-
ity compared with those in other cells.123–125 Foro-
desine (BCX-1777 or immucillin H) is a potent
inhibitor of PNP that is available orally and in IV
formulation. It has been shown to inhibit the pro-
liferation of T lymphocytes in vivo and
in vitro.121,122,126 Forodesine has been examined
in several studies for the treatment of MF/SS.
In a study of 13 patients (described as stage IIB–
IV with all but 1  stage III), IV forodesine of 40 to
320 mg/m2 was administered on day 1 followed by
8 doses every 12 hours (1 cycle) and repeated in
16-day intervals for a total of 3 cycles at 2-week in-
tervals. Nine patients (69%) showed some degree
of response.127 Duvic and colleagues128 reported
a phase I/II trial of 37 patients with stage IB or
greater CTCL. Patients were treated with oral for-
odesine, 40 to 320 mg/m2 daily for 4 weeks. It
was not reported how many of these patients rep-
resented MF/SS versus other cutaneous lym-
phomas. In patients with IIB or greater disease,
the ORR was 53.6%, including 1 patient with a
CR and 9 with a PR. The median duration of
response was 127 days. Dummer and col-
leagues129 recently published a phase II multi-
center study of forodesine in 144 individuals, in
whom 101 patients with stage IIB or greater dis-
ease were assessed for efficacy of the drug. Pa-
tients were administered 200 mg orally daily
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of 11% was noted. The lower response rate
compared with prior studies was thought possibly
due to the lower dose of medication administered
in this study.
Forodesine is generally well tolerated. Side ef-
fects include nausea, fatigue, reversible lympho-
penia, and cutaneous infections.127,129PROTEASOME INHIBITORS: BORTEZOMIB
Bortezomib (Velcade) is a cell-permeable dipep-
tide boronic acid that reversibly inhibits the b5
subunit of the proteasome. Multiple pro-
oncogenic factors are under proteasome control,
such as transcription factors, cyclins, cyclin-
dependent kinase inhibitors, and apoptotic fac-
tors.130–132 The antitumor acitivity of bortezomib
likely varies among tumor types. It is FDA
approved for IV treatment of multiple myeloma
and mantle cell lymphoma. Only 1 study has eval-
uated the efficacy of bortezomib in MF. In a phase
II trial, Zinzani and colleagues133 evaluated 10 pa-
tients with MF (1 stage IIA, 3 stage IIB, and 6 stage
IVA/B) treated with 1.3 mg/m2 twice weekly for
2 weeks followed by 1-week rest period for up to
6 cycles. A response was noted in 7 patients
(70%), including 1 CR and 6 PR. The duration of
response was 7 to 14 months; the patient with a
CR continued to be in remission 12 months after
initial response.
Bortezomib is generally well tolerated; toxicities
include neutropenia, thrombocytopenia, and sen-
sory neuropathy. In trials for multiple myeloma,
asthenia, GI symptoms, and headache were also
documented.2MULTIAGENT CHEMOTHERAPY
Although there are no large controlled studies of
multiagent chemotherapy regimens in MF/SS,
multiagent chemotherapy is the first-line treat-
ment, along with clinical trials, for most aggres-
sive/rapidly progressive CTCLs (including
transformed MF).134 Although the mainstay is the
CHOP regimen,135 first-line treatment also in-
cludes multiagent etoposide, vincristine, doxoru-
bicin, bolus cyclophosphamide, and oral
prednisone (EPOCH)136 and hyper–cyclophospha-
mide, vincristine, doxorubicin, and dexametha-
sone (CVAD) alternating with high-dose MTX and
cytarabine.137 For individuals who are candidates
for cell transplant, second-line multiagent therapy
includes dexamethasone, cisplatin, and cytara-
bine (DHAP); etoposide, methylprednisolone, cy-
tarabine, and cisplatin (ESHAP); gemcitabine,
dexamethasone, and cisplatin (GDP); gemcitabineand oxaliplatin (GemOx); ICE; and mesna, ifosfa-
mide, mitoxantrone, and etoposide
(MINE).50,134,138–143 Overall, however, the efficacy
of multiagent chemotherapy in the treatment of
MF/SS is not well established. Studies that have
evaluated various multiagent treatment regimens
have often included other concomitant treatments,
such as photopheresis or IFN administration,
further hindering evaluation of their efficacy. Addi-
tionally, despite oft-reported high initial response
rates, the duration of response is frequently short
lived. Studies that have used multiagent chemo-
therapy in MF/SS are summarized in Table 2.SUMMARY
Despite recent advances in the development of
more targeted therapies in MF/SS, traditional che-
motherapies remain an important modality for in-
duction therapy, with some agents used as
maintenance therapy. These agents generally
target proliferating cells and, therefore, have sig-
nificant toxicities. Nevertheless, as a category,
traditional chemotherapies provide remissions as
good as most other therapies and, therefore,
must be relied on until more targeted therapies
are developed. Other agents, including ILs, phos-
phorylase inhibitors, and proteasome inhibitors,
may have a more significant role in treatment after
further study.REFERENCES
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